Clinical and Pathological Characteristics of Women With Ovarian Cancers in Syria
NCT ID: NCT06253559
Last Updated: 2024-02-15
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
531 participants
Study Classification
OBSERVATIONAL
Study Start Date
2017-01-01
Study Completion Date
2023-12-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
the goal of this observational study is to describe ovarian cancer epidemiology and characteristics in Syrian women, especially during the war to do more research in the future about the risk factors of ovarian cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
NCT01422265
Ovarian Cancer
COMPLETED
Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers
NCT04795596
Ovarian Cancer
Recurrent Ovarian Carcinoma
WITHDRAWN
PHASE2/PHASE3
BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary
NCT06304922
Ovarian Cancer
NOT_YET_RECRUITING
Ovarian Malignancy Incidence in Moderate Risk Women With Low CA 125
NCT02247323
Ovarian Cancer
UNKNOWN
Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region
NCT03082976
Ovarian Cancer
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Ovarian cancer (OC) is the eighth most common cause of death worldwide, and current studies show that the death numbers caused by it will rise dramatically in the coming years. As the epidemiological features of the cancer may vary, studying these different characteristics can help us improve treatment outcomes and add preventive measures. In addition, giving special attention to these features in developing countries, or countries undergoing crisis, will help us understand the associated risk factors in these regions.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Ovarian Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
OTHER
Study Time Perspective
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ovarian cancer patients
all ovarian cancer patients that meet the criteria of the study
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* female adult (age ≥18 years)
* primary ovarian malignancy
* primary ovarian malignancy
Exclusion Criteria
* less than 18 years old
* women who have benign tumors or metastatic ovarian cancer.
* women who have benign tumors or metastatic ovarian cancer.
Minimum Eligible Age
18 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tishreen University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Apelian
Role: PRINCIPAL_INVESTIGATOR
Tishreen University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tishreen University
Latakia, , Syria
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Syria
References
Explore related publications, articles, or registry entries linked to this study.
Zheng G, Yu H, Kanerva A, Forsti A, Sundquist K, Hemminki K. Familial risks of ovarian cancer by age at diagnosis, proband type and histology. PLoS One. 2018 Oct 3;13(10):e0205000. doi: 10.1371/journal.pone.0205000. eCollection 2018.
Reference Type
BACKGROUND
Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, Setiawan VW, Visvanathan K, Weiderpass E, Adami HO, Black A, Bernstein L, Brinton LA, Buring J, Butler LM, Chamosa S, Clendenen TV, Dossus L, Fortner R, Gapstur SM, Gaudet MM, Gram IT, Hartge P, Hoffman-Bolton J, Idahl A, Jones M, Kaaks R, Kirsh V, Koh WP, Lacey JV Jr, Lee IM, Lundin E, Merritt MA, Onland-Moret NC, Peters U, Poynter JN, Rinaldi S, Robien K, Rohan T, Sandler DP, Schairer C, Schouten LJ, Sjoholm LK, Sieri S, Swerdlow A, Tjonneland A, Travis R, Trichopoulou A, van den Brandt PA, Wilkens L, Wolk A, Yang HP, Zeleniuch-Jacquotte A, Tworoger SS. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. J Clin Oncol. 2016 Aug 20;34(24):2888-98. doi: 10.1200/JCO.2016.66.8178. Epub 2016 Jun 20.
Reference Type
BACKGROUND
Yuan R, Zhang C, Li Q, Ji M, He N. The impact of marital status on stage at diagnosis and survival of female patients with breast and gynecologic cancers: A meta-analysis. Gynecol Oncol. 2021 Sep;162(3):778-787. doi: 10.1016/j.ygyno.2021.06.008. Epub 2021 Jun 16.
Reference Type
BACKGROUND
Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018 Jul;68(4):284-296. doi: 10.3322/caac.21456. Epub 2018 May 29.
Reference Type
BACKGROUND
Shanmughapriya, S., Senthilkumar, G., Arun, S., Das, B. C., & Natarajaseenivasan, K. (2016). Risk factors for epithelial ovarian carcinoma in India: A case control study in low-incidence population. International Journal of Cancer Research, 12(1), 61-68. https://doi.org/10.3923/IJCR.2016.61.68
Reference Type
BACKGROUND
Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017 Feb;14(1):9-32. doi: 10.20892/j.issn.2095-3941.2016.0084.
Reference Type
BACKGROUND
Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012 Mar;460(3):237-49. doi: 10.1007/s00428-012-1203-5. Epub 2012 Feb 10.
Reference Type
BACKGROUND
Parazzini F, Franceschi S, La Vecchia C, Fasoli M. The epidemiology of ovarian cancer. Gynecol Oncol. 1991 Oct;43(1):9-23. doi: 10.1016/0090-8258(91)90003-n.
Reference Type
BACKGROUND
Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019 Apr 30;11:287-299. doi: 10.2147/IJWH.S197604. eCollection 2019.
Reference Type
BACKGROUND
Meena RK, Syed NA, Sheikh ZA, Guru FR, Mir MH, Banday SZ, Mp AK, Parveen S, Dar NA, Bhat GM. Patterns of Treatment and Outcomes in Epithelial Ovarian Cancer: A Retrospective North Indian Single-Institution Experience. JCO Glob Oncol. 2022 Nov;8:e2200032. doi: 10.1200/GO.22.00032.
Reference Type
BACKGROUND
McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011 Aug;43(5):420-32. doi: 10.1097/PAT.0b013e328348a6e7.
Reference Type
BACKGROUND
Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):98-107.
Reference Type
BACKGROUND
the World Cancer Research Fund (WCRF), worldwide cancer data., 2020; https://www.wcrf.org/cancer-trends/worldwide-cancer-data/ )
Reference Type
BACKGROUND
Lima MA, Dos Santos L, Turri JA, Nonogaki S, Buim M, Lima JF, de Jesus Viana Pinheiro J, Bueno de Toledo Osorio CA, Soares FA, Freitas VM. Prognostic Value of ADAMTS Proteases and Their Substrates in Epithelial Ovarian Cancer. Pathobiology. 2016;83(6):316-26. doi: 10.1159/000446244. Epub 2016 Jul 1.
Reference Type
BACKGROUND
Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007 Jan;12(1):20-37. doi: 10.1634/theoncologist.12-1-20.
Reference Type
BACKGROUND
Funston G, Hamilton W, Abel G, Crosbie EJ, Rous B, Walter FM. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study. PLoS Med. 2020 Oct 28;17(10):e1003295. doi: 10.1371/journal.pmed.1003295. eCollection 2020 Oct.
Reference Type
BACKGROUND
Chornokur G, Amankwah EK, Schildkraut JM, Phelan CM. Global ovarian cancer health disparities. Gynecol Oncol. 2013 Apr;129(1):258-64. doi: 10.1016/j.ygyno.2012.12.016. Epub 2012 Dec 22.
Reference Type
BACKGROUND
Arora T, Mullangi S, Vadakekut ES, Lekkala MR. Epithelial Ovarian Cancer. 2024 May 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK567760/
Reference Type
BACKGROUND
Arora N, Talhouk A, McAlpine JN, Law MR, Hanley GE. Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada. BMC Cancer. 2018 Oct 25;18(1):1039. doi: 10.1186/s12885-018-4970-9.
Reference Type
BACKGROUND
Andrews L, Mutch DG. Hereditary Ovarian Cancer and Risk Reduction. Best Pract Res Clin Obstet Gynaecol. 2017 May;41:31-48. doi: 10.1016/j.bpobgyn.2016.10.017. Epub 2017 Jan 17.
Reference Type
BACKGROUND
Zhang S, Cheng C, Lin Z, Xiao L, Su X, Zheng L, Mu Y, Liao M, Ouyang R, Li W, Ma J, Cai J, Liu L, Wang D, Zeng F, Liu J. The global burden and associated factors of ovarian cancer in 1990-2019: findings from the Global Burden of Disease Study 2019. BMC Public Health. 2022 Jul 30;22(1):1455. doi: 10.1186/s12889-022-13861-y.
Reference Type
BACKGROUND
Saki S, Ali NR, Saki SS, AlRabeea ZS, AlRemeithi FN, Carrick FR, Abdulrahman M. Barriers to healthcare seeking, beliefs about ovarian cancer and the role of socio-economic position. A cross-sectional multilevel study in Dubai, a multicultural society. J Public Health Res. 2021 Mar 24;10(3):2073. doi: 10.4081/jphr.2021.2073.
Reference Type
BACKGROUND
Ovarian cancer statistics | World Cancer Research Fund International. (n.d.). Retrieved May 19, 2023, from https://www.wcrf.org/cancer-trends/ovarian-cancer-statistics/
Reference Type
BACKGROUND
Syria crisis . (n.d.). Retrieved May 19, 2023, from https://www.who.int/emergencies/situations/syria-crisis
Reference Type
BACKGROUND
Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000 Jul-Aug;19(1):3-10. doi: 10.1002/1098-2388(200007/08)19:13.0.co;2-s.
Reference Type
BACKGROUND
Gaona-Luviano P, Medina-Gaona LA, Magana-Perez K. Epidemiology of ovarian cancer. Chin Clin Oncol. 2020 Aug;9(4):47. doi: 10.21037/cco-20-34. Epub 2020 Jun 30.
Reference Type
BACKGROUND
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
Reference Type
BACKGROUND
Boussios S, Karathanasi A, Zakynthinakis-Kyriakou N, Tsiouris AK, Chatziantoniou AA, Kanellos FS, Tatsi K. Ovarian carcinosarcoma: Current developments and future perspectives. Crit Rev Oncol Hematol. 2019 Feb;134:46-55. doi: 10.1016/j.critrevonc.2018.12.006. Epub 2018 Dec 24.
Reference Type
BACKGROUND
Atallah GA, Abd Aziz NH, Teik CK, Shafiee MN, Kampan NC. New Predictive Biomarkers for Ovarian Cancer. Diagnostics (Basel). 2021 Mar 7;11(3):465. doi: 10.3390/diagnostics11030465.
Reference Type
BACKGROUND
Yoneda A, Lendorf ME, Couchman JR, Multhaupt HA. Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans. J Histochem Cytochem. 2012 Jan;60(1):9-21. doi: 10.1369/0022155411428469.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TishreenU -Ovarian Cancer
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Search for Predictors of Therapeutic Response in Ovarian Carcinoma
NCT01391351
COMPLETED
NA
Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer
NCT00452985
COMPLETED
Evaluation of Chemotherapy Influence on Clinical and Biological Markers of Ovarian Reserve
NCT00712452
TERMINATED
NA
Pathway to Diagnosis of Ovarian Cancer
NCT01061619
UNKNOWN
Ovarian Reserve After Cancer: Longitudinal Effects
NCT02467231
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer
NCT00772863
COMPLETED
PHASE2
Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs.
NCT02323568
COMPLETED
NA
Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma
NCT02297958
COMPLETED
Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer
NCT04752865
UNKNOWN
Constitution of ex Vivo Ovarian Tumor Models for the Validation of the Interest of Innovative Therapies and the Search for Tumor or Circulating Biomarkers Predictive of Treatment Response
NCT03831230
COMPLETED
Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer
NCT01809379
COMPLETED
PHASE2
Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer
NCT06775470
RECRUITING
Experience in Borderline Ovarian Tumors
NCT05791838
UNKNOWN
Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response
NCT00103545
COMPLETED
PHASE1/PHASE2
Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
NCT00043472
COMPLETED
Risk of Ovarian Cancer in Patients With a Pelvic Mass
NCT00315692
COMPLETED
Dysregulation of Whole-body Metabolism in Ovarian Cancer: A Longitudinal Study
NCT06800105
RECRUITING
Ovarian Tumor Biopsies to Study Response to Treatments
NCT02952521
COMPLETED
Thiol-disulfide Homeostasis in Patients With Ovarian Cancer
NCT05011539
COMPLETED
Tumor Gene Expression in Women With Ovarian Cancer
NCT00817479
COMPLETED
PHASE4
Oxford Ovarian Cancer Predict Chemotherapy Response 01
NCT01770535
UNKNOWN
Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer
NCT03611179
UNKNOWN
PHASE2
Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer
NCT06907771
RECRUITING